Amyloid beta plaques accumulated in a mouse hippocampus.
Yale researchers have identified a drinkable cocktail of designer molecules that interferes with a crucial first step of Alzheimer’s and even restores memories in mice, they report Jan. 2 in the journal Cell Reports.
The binding of amyloid beta peptides to prion proteins triggers a cascade of devasting events in the progression of Alzheimer’s — accumulation of plaques, a destructive immune system response, and damage to synapses.
“We wanted to find molecules that might have a therapeutic effect on this network,” said senior author Stephen Strittmatter, the Vincent Coates Professor of Neurology, professor of neuroscience, and director of the Yale Alzheimer Disease Research Center.
Strittmatter and research scientist Erik Gunther screened tens of thousands of compounds looking for molecules that might interfere with the damaging prion protein interaction with amyloid beta. They found that an old antibiotic looked like a promising candidate but was only active after decomposing to form a polymer. Related small polymers retained the benefit and also managed to pass through the blood-brain barrier.
They then dissolved the optimized polymeric compound and fed it to mice engineered to have a condition that mimics Alzheimer’s. They found that synapses in the brains were repaired and mice recovered lost memory.
A collaborating team at Dartmouth University reported a positive response when they delivered the same cocktail to cells modeled to have Creutzfeldt-Jakob Disease, a devasting neurological condition caused by infection with misfolded prion protein.
The next step is to verify the compounds aren’t toxic in preparation for translation to clinical trials for Alzheimer’s disease.
Learn more: New compound shows promise in treatment of Alzheimer’s
The Latest on: Designer molecules
via Google News
The Latest on: Designer molecules
- Purdue professor receives research initiative funding from Department of Defenseon March 4, 2021 at 9:28 am
Brett Savoie, the Charles Davidson Assistant Professor of Chemical Engineering at Purdue University, will lead one of 25 teams receiving Multidisciplinary University Research Initiative (MURI) funding ...
- Purdue professor receives Multidisciplinary University Research Initiative funding from Department of Defenseon March 4, 2021 at 8:21 am
Brett Savoie, the Charles Davidson Assistant Professor of Chemical Engineering at Purdue University, will lead one of 25 teams receiving Multidisciplinary University Research Initiative (MURI) funding ...
- Immunotherapies Expose and Exploit Cancer’s Varied Weaknesseson March 3, 2021 at 7:54 pm
Where some see cancer as an impenetrable, menacing cloud, others see a wispysmokescreen that barely hides multiple vulnerabilities from the immune system.
- Unique Partnership Zeroes in on Molecules That Could Fight COVID-19on March 3, 2021 at 9:01 am
Research from biologists, chemists and X-ray scientists has zeroed in on several molecules that could be used to create drugs to fight COVID-19.
- Chemists boost boron's utility: Preventing compounds from breaking down could help chemists design new drugson March 3, 2021 at 6:11 am
Boron, a metalloid element that sits next to carbon in the periodic table, has many traits that make it potentially useful as a drug component. Nonetheless, only five FDA-approved drugs contain boron, ...
- Scientists reprogram a common bacterium to make designer sugar-based drugon March 2, 2021 at 8:00 am
Envisioning an animal-free drug supply, scientists have -; for the first time -; reprogrammed a common bacterium to make a designer polysaccharide molecule used in pharmaceuticals and nutraceuticals.
- Common bacteria modified to make designer sugar-based drugon March 2, 2021 at 2:02 am
Envisioning an animal-free drug supply, scientists have—for the first time—reprogrammed a common bacterium to make a designer polysaccharide molecule used in pharmaceuticals and nutraceuticals.
- BOC Sciences Launches Ligand Design Services to Promote PROTAC Drug Developmenton February 25, 2021 at 10:07 am
BOC Sciences announced that its PROTACs technology platform can be used to provide ligand design services to promote drug development. New York, USA ...
- UChicago, Argonne scientists zero in on molecules that could fight COVID-19on February 24, 2021 at 8:18 am
A unique partnership among biologists, chemists and X-ray scientists at UChicago and Argonne has zeroed in on several molecules that could be used to create drugs to fight COVID-19.
- Salk team reveals never-before-seen antibody binding, informing both liver cancer and antibody designon February 20, 2021 at 8:00 am
That’s precisely how a multi-institutional research team led by Salk scientists defined how antibodies can recognize a compound called phosphohistidine — a highly unstable molecule that has been found ...
via Bing News
